DRAXIS HEALTH INC 
By
Details of the conference call and webcast are as follows:
-------------------------------------------------------------------------
Date/time Thursday February 7, 2008 at 10:00 a.m. (ET)
-------------------------------------------------------------------------
Dial-in number 1 (866) 321-6651 ACCESS CODE 8659140
and access code
-------------------------------------------------------------------------
Audio webcast Access the live call on the DRAXIS web site at
www.draxis.com
The call will be archived on the web site for 30 days.
-------------------------------------------------------------------------
Audio Player You will require the Windows Media Player,
downloadable free from
http://www.microsoft.com/windows/windowsmedia/download/default.asp
-------------------------------------------------------------------------
Playback An audio playback of the call will be available until
midnight February 14, 2008.
To listen, dial 1 (888) 203-1112 and refer to access
code 8659140.
-------------------------------------------------------------------------
About DRAXIS Health Inc.:
DRAXIS Health, through its wholly owned operating subsidiary, DRAXIS
Specialty Pharmaceuticals Inc., provides products in three categories: sterile
products, non-sterile products and radiopharmaceuticals. Sterile products
include liquid and freeze-dried (lyophilized) injectables plus sterile
ointments and creams. Non-sterile products are produced as solid oral and
semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic
and diagnostic molecular imaging applications. Pharmaceutical contract
manufacturing services are provided through the DRAXIS Pharma division and
radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE
division. DRAXIS employs approximately 500 staff in its
For additional information please visit www.draxis.com
Caution Concerning Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and as contemplated under other applicable securities legislation. These statements can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "plan," "intend," "believe" or other similar words. These statements discuss future expectations concerning results of operations or financial condition or provide other forward-looking information. Our actual results, performance or achievements could be significantly different from the results expressed in, or implied by, those forward-looking statements. You should not place undue reliance on any forward-looking statement, which speaks only as of the date made.
These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors that could cause the Company's results or performance to differ materially from a conclusion, forecast or projection in the forward-looking statements include, but are not limited to:
- the achievement of desired clinical trial results related to the
Company's pipeline products;
- timely regulatory approval of the Company's products;
- the ability to comply with regulatory requirements applicable to the
manufacture and marketing of the Company's products;
- the Company's ability to obtain and enforce effective patents;
- the non-infringement of third party patents or proprietary rights by
the Company and its products;
- factors beyond our control that could cause interruptions in our
operations in our single manufacturing facility (including, without
limitation, material equipment breakdowns);
- reimbursement policies related to health care;
- the establishment and maintenance of strategic collaborative and
commercial relationships;
- the Company's dependence on a small number of key customers;
- the disclosure of confidential information by our collaborators,
employees or consultants;
- the preservation of healthy working relationships with the Company's
union and employees;
- the Company's ability to grow the business;
- the fluctuation of our financial results and exchange and interest
rate fluctuations;
- the adaptation to changing technologies;
- the loss of key personnel;
- the avoidance of product liability claims;
- the loss incurred if current lawsuits against us succeed;
- the volatility of the price of our common shares;
- market acceptance of the Company's products;
- factors described under "Outlook" in the MD&A for the Company's most
recent quarter; and
- the risks described in "Item 3. Key Information - Risk Factors" in
the Annual Report Form 20-F filed by the Company with the United
States Securities and Exchange Commission and which is also filed as
the Company's Annual Information Form with Canadian securities
regulators.
For additional information with respect to certain of these and other
factors, and relating to the Company generally, reference is made to the
Company's most recent filings with the
SOURCE DRAXIS Health Inc.
